ERBB2 and endometrial cancer: By achieving a median PFS of 16 weeks and a median OS of 61 weeks across all patients, the study demonstrated that the combination of pertuzumab and trastuzumab exhibits antitumor activity in heavily pretreated patients with endometrial cancer harboring ERBB2/3 amplification [127].